Tempus AI announced a new multi-year strategic collaboration with Boehringer Ingelheim to advance its growing cancer pipeline. This collaboration builds on foundational work the two companies have conducted in previous years, leveraging data and AI to further therapeutic research and development.
Under this new agreement, Boehringer Ingelheim will gain access to Tempus’ de-identified database, which contains molecular, clinical, and imaging data, as well as its analytical platform, Lens. The objective is to explore data derived from patient cohorts to guide biomarker development and patient stratification.
The collaboration also aims to develop drug combination hypotheses, support novel target discovery efforts, and educate on patients’ healthcare journeys. This partnership underscores the commitment of both companies to applying data and AI to bring novel cancer treatments to patients faster.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.